English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Cases of severely exacerbated CNS inflammation have been described in patients with MS under treatment with alemtuzumab, a pan-lymphocyte–depleting anti-CD52 monoclonal antibody.1,2 On the basis of the peripheral lymphocyte subset network (higher B-cell and suppressed T-cell counts)2 and marked clinical improvement following plasmapheresis and rituximab treatment (anti-CD20 antibody),1 a B-cell–driven intrathecal autoimmune reaction was hypothesized.Acknowledgment: The authors thank Dr. Lucia Rossi, of the Virology Section of the Department of Molecular Medicine, University of Padua, for EBV DNA testing in blood and CSF.

Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy